Skip to main content
MedPathMedPath Home
Clinical Trials/DRKS00024434
DRKS00024434
Not yet recruiting
Not Applicable

Immune-mediated pathogenesis and development of autoimmunity in neurological manifestations of COVID-19 - IPEA

niversity of Cologne0 sites150 target enrollmentFebruary 5, 2021
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsONG COVID, cognitive deficits during COVID-19 infection, psychiatric disease after COVID-19 infection, immunological marker and divergence in serum and cerebro spinal fluid during COVID infectionU07.1COVID-19, virus identified

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
ONG COVID, cognitive deficits during COVID-19 infection, psychiatric disease after COVID-19 infection, immunological marker and divergence in serum and cerebro spinal fluid during COVID infection
Sponsor
niversity of Cologne
Enrollment
150
Status
Not yet recruiting
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
February 5, 2021
End Date
TBD
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Sponsor
niversity of Cologne

Eligibility Criteria

Inclusion Criteria

  • •Informed consent
  • •no drug or alcohol addiction
  • •german language

Exclusion Criteria

  • •not able to give informed consent, under\-age, no juristical supervisor

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
The role of innate immunity in the pathogenesis of acute respiratory syncytial virus lower respiratory tract infection: Repeated measurements of nasopharyngeal type 1 interferon levels in RSV infectionsInnate immune responseViral respiratory tract infection10024970
NL-OMON35329RSV Research Group van het Wilhelmina Kinderziekenhuis Utrecht, UMCU, onder leiding van Prof. dr. J.L.L. Kimpen, promotor400
Not yet recruiting
Phase 2
Examinations for immune-biological mechanism of anti-atherosclerotic effects of omega 3 lipid formula, Lotriga, focusing on commensal microbe and serum auto-antibodies.The subjects with hyper-triglyceridemia and atherosclerosis.
JPRN-UMIN000032320Yokohama City University Graduate School of Medicine, Department of Medical Science and Cardio-Renal Medicine36
Completed
Not Applicable
Immunogenetic and therapeutic aspects of Autoimmune Hepatitis
NL-OMON44835Vrije Universiteit Medisch Centrum2,000
Active, not recruiting
Not Applicable
Investigation of immune mechanisms relating to lapatinib associated hepatotoxicity (liver toxicity)The subjects participated in the EGF105485 study, a randomized, placebo-controlled study of lapatinib in HER2-positive early-stage breast cancer. During participation in this study, subjects had blood test results that may be suggestive of liver damage.Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2013-000572-15-ESGlaxoSmithKline, S.A.75
Active, not recruiting
Not Applicable
Investigation of immune mechanisms relating to lapatinib associated hepatotoxicity (liver toxicity)
EUCTR2013-000572-15-DKGlaxoSmithKline Research & Development Ltd75